Nexalin Technology (NXL) Change in Accured Expenses (2022 - 2026)
Nexalin Technology (NXL) posted quarterly Change in Accured Expenses of -$2489.0 for Q1 2026, down 195.84% year-over-year from $2597.0 in Q1 2025, and down 100.78% quarter-over-quarter from $318723.0 in Q4 2025.
Nexalin Technology (NXL) Change in Accured Expenses (2022 - 2026) Analysis & Trends
Nexalin Technology's Change in Accured Expenses history runs 5 years deep, the most recent figure standing at -$2489.0 for Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 195.84% year-over-year to -$2489.0; the TTM figure through Mar 2026 stood at $246923.0 (up 556.2% YoY), while the FY2025 annual figure was $252009.0, up 94.66% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$2489.0, down from $318723.0 in the prior quarter.
- The five-year high for Change in Accured Expenses was $318723.0 in Q4 2025, with the low at -$230747.0 in Q2 2024.
- The 5-year median for Change in Accured Expenses is $5973.0 (2023), against an average of $18502.9.
- The sharpest annual moves came in 2023 and 2024: Change in Accured Expenses jumped 316.82% in 2023, then tumbled 3963.17% in 2024.
- Nexalin Technology's Change in Accured Expenses stood at $97322.0 in 2022, then slumped by 336.95% to -$230607.0 in 2023, then soared by 211.83% to $257898.0 in 2024, then rose by 23.58% to $318723.0 in 2025, then sank by 100.78% to -$2489.0 in 2026.
- Business Quant data shows NXL's Change in Accured Expenses at -$2489.0 in Q1 2026, $318723.0 in Q4 2025, and -$47973.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.63 Bn | 194.02 Bn | 7.27 Bn | - |
| 2 | Stryker | 127.42 Bn | 123.95 Bn | 4.50 Bn | 298.00 Mn |
| 3 | Medtronic | 118.97 Bn | 109.75 Bn | 6.41 Bn | 123.00 Mn |
| 4 | Boston Scientific | 73.39 Bn | 72.85 Bn | 3.85 Bn | 234.00 Mn |
| 5 | Edwards Lifesciences | 51.97 Bn | 47.72 Bn | 1.35 Bn | 123.70 Mn |
| 6 | Dexcom | 34.32 Bn | 32.37 Bn | 830.00 Mn | 112.90 Mn |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.65 Bn | 2.18 Bn | 19.00 Mn |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | 43.01 Mn |
| 9 | Steris | 23.04 Bn | 22.56 Bn | 684.20 Mn | 4.80 Mn |
| 10 | Nexalin Technology | 7.01 Mn | 6.00 Mn | 8,897.00 | 218,239.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 218,239.00 |
| Jun 30, 2026 | 218,239.00 |
| Mar 31, 2026 | -2,489.00 |
| Mar 31, 2026 | -2,489.00 |
| Dec 31, 2025 | 318,723.00 |
| Dec 31, 2025 | 318,723.00 |
| Sep 30, 2025 | -47,973.00 |
| Sep 30, 2025 | -47,973.00 |
| Jun 30, 2025 | -21,338.00 |
| Jun 30, 2025 | -21,338.00 |
| Mar 31, 2025 | 2,597.00 |
| Mar 31, 2025 | 2,597.00 |
| Dec 31, 2024 | 257,898.00 |
| Dec 31, 2024 | 257,898.00 |
| Sep 30, 2024 | 7,881.00 |
| Sep 30, 2024 | 7,881.00 |
| Jun 30, 2024 | -230,747.00 |
| Jun 30, 2024 | -230,747.00 |
| Mar 31, 2024 | 94,429.00 |
| Mar 31, 2024 | 94,429.00 |